Literature DB >> 27472209

Globe size and bevacizumab treatment in retinopathy of prematurity: should we adjust the dose?

A J Connor1, A Shafiq1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27472209      PMCID： PMC5108023          DOI： 10.1038/eye.2016.173

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  5 in total

1.  Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity.

Authors:  Alan J Connor; Vasileios T Papastavrou; Roxane J Hillier; Ayad Shafiq
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2015-04-30       Impact factor: 1.402

Review 2.  A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity.

Authors:  Jonathan A Micieli; Michael Surkont; Andrew F Smith
Journal:  Am J Ophthalmol       Date:  2009-08-05       Impact factor: 5.258

3.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

Authors:  Helen A Mintz-Hittner; Kathleen A Kennedy; Alice Z Chuang
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245

4.  Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors.

Authors:  Tim U Krohne; Philipp S Muether; Nina K Stratmann; Frank G Holz; Bernd Kirchhof; Carsten H Meyer; Sascha Fauser
Journal:  Retina       Date:  2015-01       Impact factor: 4.256

Review 5.  On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review.

Authors:  Anna-Lena Hård; Ann Hellström
Journal:  Acta Paediatr       Date:  2011-09-29       Impact factor: 2.299
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.